Cabozantinib

Generic Name
Cabozantinib
Brand Names
Cabometyx, Cometriq
Drug Type
Small Molecule
Chemical Formula
C28H24FN3O5
CAS Number
849217-68-1
Unique Ingredient Identifier
1C39JW444G
Background

Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...

Indication

⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。

⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。

Associated Conditions
Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
Associated Therapies
-
Clinical Trials
Related News

CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation

Phase 2
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: Cabozantinib
First Posted Date
2019-04-11
Last Posted Date
2019-04-11
Lead Sponsor
Fondazione Ricerca Traslazionale
Target Recruit Count
25
Registration Number
NCT03911193
Locations
🇮🇹

Azienda Ospedaliero- Universitaria di Parma, Parma, PR, Italy

🇮🇹

A.O. S.M. Misericordia, Perugia, PG, Italy

🇮🇹

Azienda Ospedaliero Universitaria Pisana, Pisa, PI, Italy

and more 17 locations

Pan Tumor Rollover Study

First Posted Date
2019-04-02
Last Posted Date
2024-11-19
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1500
Registration Number
NCT03899155
Locations
🇧🇷

Local Institution - 0260, Belo Horizonte, Minas Gerais, Brazil

🇨🇳

Harbin Medical University - Cancer Hospital, Harbin, Heilongjiang, China

🇨🇳

Local Institution - 0172, Changsha, Hunan, China

and more 304 locations

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

First Posted Date
2019-04-02
Last Posted Date
2024-02-28
Lead Sponsor
Humanity & Health Medical Group Limited
Target Recruit Count
30
Registration Number
NCT03899428
Locations
🇭🇰

Humanity & Health Research Centre, Hong Kong, Hong Kong SAR, Hong Kong

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma
Interventions
Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat
First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"

First Posted Date
2019-01-31
Last Posted Date
2021-02-25
Lead Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Target Recruit Count
122
Registration Number
NCT03824691
Locations
🇮🇹

Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

First Posted Date
2019-01-10
Last Posted Date
2024-11-27
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
167
Registration Number
NCT03798626
Locations
🇺🇸

University of California LA, Los Angeles, California, United States

🇺🇸

WA Uni School Of Med, Saint Louis, Missouri, United States

🇺🇸

Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 1 locations

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

First Posted Date
2019-01-04
Last Posted Date
2024-12-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
1175
Registration Number
NCT03793166
Locations
🇺🇸

Northside Hospital - Gwinnett, Lawrenceville, Georgia, United States

🇺🇸

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States

🇺🇸

Hawaii Cancer Care - Westridge, 'Aiea, Hawaii, United States

and more 862 locations

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

First Posted Date
2018-12-07
Last Posted Date
2024-12-20
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1000
Registration Number
NCT03768063
Locations
🇺🇸

Univ of Alabama at Birmingham; UAB Comprehensive Cancer Ctr, Birmingham, Alabama, United States

🇺🇸

HonorHealth Research Institute - Pima - Virginia G. Piper Cancer Care Network, Scottsdale, Arizona, United States

🇺🇸

University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute, Little Rock, Arkansas, United States

and more 199 locations

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy

Phase 3
Active, not recruiting
Conditions
Hepatocellular Carcinoma
Interventions
Drug: Cabozantinib
Drug: Sorafenib
Drug: Atezolizumab
First Posted Date
2018-11-28
Last Posted Date
2024-03-22
Lead Sponsor
Exelixis
Target Recruit Count
837
Registration Number
NCT03755791
Locations
🇺🇸

Exelixis Clinical Site #88, Philadelphia, Pennsylvania, United States

🇦🇺

Exelixis Clinical Site #78, Camperdown, New South Wales, Australia

🇺🇸

Exelixis Clinical Site #7, Burlington, Massachusetts, United States

and more 242 locations

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

First Posted Date
2018-11-02
Last Posted Date
2023-04-11
Lead Sponsor
Nektar Therapeutics
Target Recruit Count
623
Registration Number
NCT03729245
Locations
🇺🇸

Alaska Urological, Anchorage, Alaska, United States

🇺🇸

CARTI Cancer Center, Little Rock, Arkansas, United States

🇦🇷

Centro de Investigación Pergamino S.A, Buenos Aires, Argentina

and more 92 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy